Insider Selling: Guardant Health Inc (NASDAQ:GH) Insider Sells 63,075 Shares of Stock
Guardant Health Inc (NASDAQ:GH) insider Richard B. Lanman sold 63,075 shares of Guardant Health stock in a transaction on Friday, August 9th. The stock was sold at an average price of $105.25, for a total transaction of $6,638,643.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Guardant Health stock traded up $2.64 during trading on Tuesday, hitting $101.27. 1,544,570 shares of the stock were exchanged, compared to its average volume of 1,018,844. The company has a market cap of $9.15 billion and a PE ratio of -36.17. The business’s 50-day simple moving average is $91.64. Guardant Health Inc has a 12-month low of $27.04 and a 12-month high of $112.21.
Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.21. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. The business had revenue of $53.98 million during the quarter, compared to analysts’ expectations of $35.97 million. During the same period in the previous year, the company earned ($1.75) EPS. The company’s revenue for the quarter was up 178.5% on a year-over-year basis. Research analysts predict that Guardant Health Inc will post -1.27 earnings per share for the current year.
GH has been the subject of several recent analyst reports. Cowen set a $110.00 price objective on shares of Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Zacks Investment Research cut shares of Guardant Health from a “strong-buy” rating to a “hold” rating in a research report on Saturday. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $125.00 price objective (up from $96.00) on shares of Guardant Health in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $111.80.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Recommended Story: What is the definition of a trade war?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.